Edwards Lifesciences Corporation

EW

Find Out if You Qualify for a Financial Reward by filling out the form below.

Lead Plaintiff Deadline:
December 13, 2024

Days Left:
57

calendar

Allegations

According to the complaint, defendants provided investors with material information concerning Edwards’ expected revenue for the fiscal year 2024, particularly as it related to the growth of the Company’s core product, Transcatheter Aortic Valve Replacement (“TAVR”). Defendants’ statements included, among other things, strong commitment to the TAVR platform, confidence in the Company’s ability to capitalize on a subset of untreated patients through scaling of its various patient activation activities, and continued claims of significant demand in allegedly lower-penetrated markets. On July 24, 2024, Edwards unveiled below-expectation financial results for the second quarter of fiscal 2024 and, in particular, slashed its revenue guidance for the TAVR platform for the full fiscal year 2024. The Company attributed the TAVR setback on the “continued growth and expansion of structural heart therapies … [which] put pressure on hospital workflows.” Investors understood this to mean that developments in new procedures, including defendant’s own Transcatheter Mitral and Tricuspid Therapies (“TMTT”), put significant strain on hospital structural heart teams such that they were underutilizing TAVR, despite the Company’s continued claim of a significantly undertreated patient population. Moreover, the Company announced three acquisitions during the second quarter designed to embolden their treatments alternative to TAVR, suggesting further that the company was aware of the potential for the TAVR platform’s decelerated growth. Investors and analysts reacted immediately to Edwards’ revelations. The price of Edwards’ common stock declined dramatically. From a closing market price of $86.95 per share on July 24, 2024, Edwards’ stock price fell to $59.70 per share on July 25, 2024, a decline of about 31.34% in the span of just a single day.

Eligibility

In order to be included in the lawsuit, you must have incurred a loss on shares of Edwards purchased or acquired during the class period listed above.

Lead Plaintiff Deadline

If you suffered a loss in Edwards during the relevant time frame, you have until December 13, 2024 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Find More Cases

Ticker Symbol Company Name Deadline
OFIX Orthofix Medical Inc. October 21, 2024 View
DXCM DexCom, Inc. October 21, 2024 View
SPIR Spire Global, Inc. October 21, 2024 View
STM STMicroelectronics N.V. October 22, 2024 View
DAVA Endava plc October 25, 2024 View
MEI Methode Electronics, Inc. October 25, 2024 View
SAGE Sage Therapeutics, Inc. October 28, 2024 View
VERV Verve Therapeutics, Inc. October 28, 2024 View
SBUX Starbucks Corporation October 28, 2024 View
OM Outset Medical, Inc. October 28, 2024 View
SMCI Super Micro Computer, Inc. October 29, 2024 View
ZI ZoomInfo Technologies Inc. November 04, 2024 View
WBTN WEBTOON Entertainment Inc. November 04, 2024 View
GTLB GitLab Inc. November 04, 2024 View
GTLB GitLab Inc. November 04, 2024 View
AGEN Agenus Inc. November 05, 2024 View
NFE New Fortress Energy Inc. November 18, 2024 View
DPZ Domino's Pizza, Inc. November 19, 2024 View
MGX Metagenomi, Inc. November 25, 2024 View
BMBL Bumble Inc. November 25, 2024 View
LLAP Terran Orbital Corporation November 26, 2024 View
LLAP Terran Orbital Corporation November 26, 2024 View
FNA Paragon 28, Inc. November 29, 2024 View
ELAN Elanco Animal Health Incorporated December 06, 2024 View
IREN Iris Energy Limited December 06, 2024 View
AILE iLearningEngines, Inc. December 06, 2024 View
UPS United Parcel Service, Inc. December 09, 2024 View
EW Edwards Lifesciences Corporation December 13, 2024 View